Compare FUND & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUND | PROK |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.4M | 417.1M |
| IPO Year | N/A | N/A |
| Metric | FUND | PROK |
|---|---|---|
| Price | $8.64 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 32.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | ★ $744,000.00 |
| Revenue This Year | N/A | $918.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.75 | $0.46 |
| 52 Week High | $8.47 | $7.13 |
| Indicator | FUND | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 42.40 |
| Support Level | $8.65 | $2.09 |
| Resistance Level | $8.95 | $2.29 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 61.18 | 28.69 |
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, The Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.